Genmab — December 2020
-
"the PD-L1x4-1BB dual body [] has broad potential in a range of solid tumors, including those where checkpoint therapy is currently established but also more difficult tumors where first-generation checkpoint inhibitors have not been as successful. This bispecific antibody has outperformed conventional checkpoint inhibitors in preclinical animal models. We have seen strong evidence in the preclinical setting of its ability to amplify the effect of our vaccines as well."
-
Aktien opfører sig lige som den har gjort det i en del dage på det seneste. Fald fra morgenstunden og indhentning sidst på dagen.
-
Det er positivt at vi ser højere bunde.
-
Det har du desværre ret i.
-
Det blev ikke en højere bund i dag.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind